HR 3375 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Fair Prescription Drug Prices for Americans Act
To require that the retail list price for certain prescription drugs and biological products may not exceed the average retail list price for the drug or biological product among certain nations.
Summary
This bill establishes a price cap for prescription drugs and biological products sold in the United States based on international reference pricing. The retail list price for a drug or biological product in the U.S. may not exceed the average retail list price for that same drug or product in Canada, France, Germany, Italy, Japan, and the United Kingdom. The Secretary of Health and Human Services must calculate this average price annually using data reported by manufacturers and publicly available information from those countries. Manufacturers are required to submit annual reports showing their list prices in the U.S. and in each of the six comparison countries. Manufacturers that exceed the price cap are subject to a civil monetary penalty equal to 10 times the price difference, calculated per unit sold, and the Secretary must issue regulations to implement these requirements.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
Money behind the sponsor
Top reported contributors to Jefferson Van Drew’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- NULL $176,557
- ENTREPRENEUR $70,972
- PULSE VASCULAR $9,900
- ICONA RESORTS $9,900
- MONZO CATANESE HILLEGASS $9,000
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Jefferson Van Drew → · Outside spending →
Actions (2)
- May 13, 2025 Referred to the House Committee on Energy and Commerce. · house
- May 13, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
May 13, 2025
Mr. Van Drew introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To require that the retail list price for certain prescription drugs and biological products may not exceed the average retail list price for the drug or biological product among certain nations.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Fair Prescription Drug Prices for Americans Act”.
SEC. 2. INTERNATIONAL REFERENCE PRICING FOR PRESCRIPTION DRUGS AND BIOLOGICAL PRODUCTS.
(a) Definitions.—In this section:
(1) Biological product.—The term “biological product” means a biological product licensed under subsection (a) or (k) of section 351 of the Public Health Service Act (42 U.S.C.
262).
(2) Drug.—The term “drug” means a drug approved under subsection (c) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355).
(3) Secretary.—The term “Secretary” means the Secretary of Health and Human Services.
(b) Cap on Retail List Price of Prescription Drugs and Biological Products.—The retail list price in the United States for a drug or a biological product may not exceed the average retail list price for the drug or biological product among Canada, France, Germany, Italy, Japan, and the United Kingdom, as calculated under subsection (c).
(c) Calculation of Average Retail List Price.—The Secretary shall calculate on an annual basis the average retail list price for each drug and biological product sold in Canada, France, Germany, Italy, Japan, and the United Kingdom, through a combination of data reported by manufacturers of drugs and biological products under subsection (e) and data obtained through review of publicly filed materials by manufacturers of drugs and biological products in such countries.
(d) Civil Monetary Penalty.—
(1) In general.—Any manufacturer that violates subsection
(b) with respect to a drug or biological product shall be subject to a civil monetary penalty imposed by the Secretary in amount equal to the product obtained by multiplying—
(A) the difference between—
(i) the list price for the drug or biological product sold in the United States; and
(ii) the average retail list price for the drug or biological product sold in Canada, France, Germany, Italy, Japan, and the United Kingdom, as calculated under subsection (c); and
(B) 10.
(2) Requirement.—The amount of a civil monetary penalty under paragraph (1) shall be calculated and charged for each unit of drug or biological product sold.
(e) Data Collection.—Each manufacturer of a drug or biological product shall submit to the Secretary on an annual basis—
(1) the list price for the drug or biological product sold in the United States; and
(2) the list price for the drug or biological product sold in each of Canada, France, Germany, Italy, Japan, and the United Kingdom.
(f) Guidance and Regulations.—The Secretary shall issue guidance and promulgate regulations to implement this section. <all>
Comments